2-(4-Chloro-phenyl)-5,6-dihydroxy-pyrimidine-4-carboxylic acid

ID: ALA188448

Chembl Id: CHEMBL188448

PubChem CID: 135434387

Max Phase: Preclinical

Molecular Formula: C11H7ClN2O4

Molecular Weight: 266.64

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  O=C(O)c1nc(-c2ccc(Cl)cc2)nc(O)c1O

Standard InChI:  InChI=1S/C11H7ClN2O4/c12-6-3-1-5(2-4-6)9-13-7(11(17)18)8(15)10(16)14-9/h1-4,15H,(H,17,18)(H,13,14,16)

Standard InChI Key:  XNDKQQKHTBDWNQ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA188448

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 266.64

Molecular Weight (Monoisotopic): 266.0094

AlogP: 1.91

#Rotatable Bonds: 2

Polar Surface Area: 103.54

Molecular Species: ZWITTERION

HBA: 5

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 0.05

CX Basic pKa: 16.02

CX LogP: 1.29

CX LogD: -0.04

Aromatic Rings: 2

Heavy Atoms: 18

QED Weighted: 0.77

Np Likeness Score: -1.07

References

1. Summa V, Petrocchi A, Matassa VG, Taliani M, Laufer R, De Francesco R, Altamura S, Pace P..  (2004)  HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis.,  47  (22): [PMID:15481971] [10.1021/jm0494669]

2. Lacbay CM, Menni M, Bernatchez JA, Götte M, Tsantrizos YS..  (2018)  Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively "Freeze" the pre-translocated complex during the polymerization catalytic cycle.,  26  (8): [PMID:29478802] [10.1016/j.bmc.2018.02.017]

Source

Source(1):

• Scientific Literature